Telix Pharmaceuticals Ltd (ASX:TLX) is back on investors’ radars this week after RBC Capital Markets initiated coverage, arguing the stock now looks undervalued following a sharp and prolonged sell-off.
Telix shares were trading around $11.75 on Tuesday afternoon, down more than 50% over the past six months and almost 20% over the past five days. The stock peaked at $31.14 in late February, before a sequence of regulatory and legal developments steadily eroded confidence.
RBC initiated coverage with a price target of $17 per share, implying upside of about 30%. The call comes after a difficult year for Telix shares, shaped by delays and operational challenges and the emergence of US securities class actions that have added another layer of uncertainty. At the same time, the company has continued to push forward with its late-stage prostate cancer therapeutic program and remediation work tied to its imaging assets.
That tension has resurfaced in recent sessions, with fresh headlines linked to the class actions appearing alongside RBC’s valuation work. The renewed legal visibility has kept pressure on the stock, even as Telix points to incremental progress across its pipeline and regulatory pathways.
Regulatory delays set the tone
The slide in Telix shares has not been driven by a collapse in its core commercial business. Its prostate cancer imaging agents, Illuccix and Gozellix, remain approved and in market, and the company has not withdrawn revenue guidance tied to those products. Instead, sentiment has turned on the fate of pipeline assets beyond that base.
The first inflection point came in April, when the US Food and Drug Administration issued a Complete Response Letter for TLX101-CDx, an imaging agent for glioma. The FDA did not raise safety concerns, but requested additional confirmatory clinical evidence, delaying a pathway that had been widely expected to progress more smoothly.
A second, more damaging setback followed in late August. The FDA issued a CRL for TLX250-CDx, a kidney cancer imaging agent with Breakthrough Therapy designation, citing deficiencies in Chemistry, Manufacturing and Controls. The issues extended to third-party manufacturing and supply-chain partners, raising questions about scalability and remediation timelines.
For investors, that distinction mattered. Clinical delays can often be modelled; manufacturing comparability issues are harder to forecast, particularly in radiopharmaceuticals. The sell-off following the August disclosure marked a clear shift in how the market was prepared to value the company — and the stock has struggled to regain footing since.
Legal overhang adds another layer
Those regulatory disclosures now underpin the US securities class actions filed against Telix. Plaintiffs allege the company overstated aspects of pipeline readiness and supply-chain robustness earlier in 2025, with losses crystallising when the FDA decisions and a disclosed SEC subpoena came to light.
While the litigation itself remains at an early stage, it reappeared in headlines this week as US law firms circulated reminders tied to the class actions ahead of a January lead-plaintiff deadline. The notices have kept legal risk visible in the market, even as attention shifts back to valuation and regulatory progress.
Progress continues beneath the noise
Operationally, Telix has continued to move. Earlier this month, the company dosed the first patient in the randomised expansion phase of its global Phase 3 ProstACT trial for TLX591, its lead prostate cancer therapeutic candidate. The study combines a PSMA-targeted radio-antibody drug conjugate with standard-of-care treatments and is designed to enrol hundreds of patients globally.
Telix has also agreed a resubmission pathway with the FDA for TLX101-CDx following a Type A meeting, and is progressing remediation work for TLX250-CDx to address the manufacturing issues raised in the CRL. Both these assets remain central to the company’s longer-term strategy.
RBC reframes the valuation question
Against that backdrop, RBC argues that Telix’s share price decline has left the stock trading below its assessment of fair value, with the broker pointing to a valuation anchored in existing commercial revenues and longer-dated pipeline optionality rather than near-term regulatory wins.
For now, Telix remains in a familiar biotech holding pattern: operational progress continuing, patience wearing thin, and sentiment waiting on clearer regulatory outcomes to determine whether this year’s sell-off proves excessive — or merely unfinished.